IP Library Granted Patent US 8,273,876
Granted Patent B2
US 8,273,876 · App. 10/521,534 · Granted Sep 25, 2012

Medicaments containing vardenafil hydrochloride trihydrate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,876
App. No.
10/521,534
Granted
Sep 25, 2012
Kind
B2
Abstract

The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.

Claims (25)

1. A method for producing medicaments in the form of a coated tablet comprising vardenafil hydrochloride trihydrate and one or more excipients, said method comprising the steps of

a) providing a tablet containing vardenafil hydrochloride, irrespective of which polymorphic form or mixture of polymorphic forms of vardenafil hydrochloride is initially present in the tablet, plus one or more excipients including a disintegrant;

b) treating said tablet with a moistened gas for sufficient time to convert at least 90 mol % of the vardenafil hydrochloride into the trihydrate form; and

c) coating said tablet with a coating agent.

2. The method as claimed in claim 1 , wherein air is employed as the moistened gas.

3. The method as claimed in claim 2 , wherein the moistened gas has a relative humidity of from 35% to 100%.

4. A method for the treatment of erectile dysfunction comprising administering to a subject an effective amount of the coated tablet made by the method of claim 1 .

5. A method for the treatment of sexual dysfunctions comprising administering to a subject an effective amount of the coated tablet made by the method of claim 1 .

6. The method of claim 3 , wherein the moistened gas has a relative humidity of from 50% to 99%.

7. The method of claim 3 , wherein said tablet is treated with the moistened gas for from 0.5 hours to 6 months.

8. The method of claim 3 , wherein said tablet is treated with the moistened gas at temperatures of 16 to 30° C.

9. The method of claim 1 , wherein said disintegrant is selected from the group consisting of microcrystalline cellulose, crospovidone, and mixtures thereof.

10. The method of claim 1 , wherein said coating agent is selected from the group consisting of hypromellose, macrogol, and mixtures thereof.

11. The method of claim 1 , wherein said coated tablet as produced contains a disintegrant and a coating agent, wherein the disintegrant is selected from the group consisting of microcrystalline cellulose, crospovidone, and mixtures thereof, and the coating agent is selected from the group consisting of hypromellose, macrogol, and mixtures thereof.

12. A method for producing medicaments in the form of a coated tablet comprising vardenafil hydrochloride trihydrate and one or more excipients, said method comprising the steps of

a) providing a tablet containing vardenafil hydrochloride, irrespective of which polymorphic form or mixture of polymorphic forms of vardenafil hydrochloride is initially present in the tablet, plus one or more excipients including a disintegrant;

b) coating said tablet with a coating agent; and

c) treating said tablet with a moistened gas for sufficient time to convert at least 90 mol % of the vardenafil hydrochloride into the trihydrate form.

13. The method as claimed in claim 12 , wherein air is employed as the moistened gas.

14. The method as claimed in claim 13 , wherein the moistened gas has a relative humidity of from 35% to 100%.

15. A method for the treatment of erectile dysfunction comprising administering to a subject an effective amount of the coated tablet made by the method of claim 12 .

16. A method for the treatment of sexual dysfunctions comprising administering to a subject an effective amount of the coated tablet made by the method of claim 12 .

17. The method of claim 12 , wherein said disintegrant is selected from the group consisting of microcrystalline cellulose, crospovidone, and mixtures thereof.

18. The method of claim 12 , wherein said coating agent is selected from the group consisting of hypromellose, macrogol, and mixtures thereof.

19. The method of claim 12 , wherein said coated tablet as produced contains a disintegrant and a coating agent, wherein the disintegrant is selected from the group consisting of microcrystalline cellulose, crospovidone, and mixtures thereof, and the coating agent is selected from the group consisting of hypromellose, macrogol, and mixtures thereof.

Assignments (6)
CHANGE OF ADDRESS Recorded Jun 12, 2023
From: BAYER INTELLECTUAL PROPERTY GMBH
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 064021/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 029908/0217 →
CHANGE OF NAME Recorded Apr 23, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 028093/0091 →
CONFIRMATORY ASSIGNMENT Recorded Apr 23, 2012
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 028093/0393 →
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2006
From: SERNO, PETER; GRUNENBERG, ALFONS; OHM, ANDREAS; BELLINGHAUSEN, RAINER; HENCK, JAN-OLAV; VOLLERS, EIMER
To: BAYER HEALTHCARE AG
Reel/Frame 016999/0747 →